
Lilly and Hims & Hers Offer Zepbound and Foundayo at Self-Pay Prices Starting at $149 and $299
Notas del episodio
Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible patients who receive a prescription from a licensed provider on the platform can get the medicines at Lilly's self-pay prices without leaving the platform, with home shipment after consultation. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. Hims & Hers has never offered compounded copies of Lilly's GLP-1s and committed not to do so; the companies also said they will protect independent clinical decision-making. The arrangement puts Lilly on similar footing with Novo Nordisk's earlier branded-access deal with Hims & Hers.
Sources
- Eli Lilly IR joint release (Nov 6, 2026): investor.lilly.com
- Reuters via U.S. News Money (Nov 6, 2026): money.usnews.com
- BioPharma Dive (Nov 6, 2026): biopharmadive.com
- pharmaphorum (Nov 6, 2026): pharmaphorum.com
- BariatricPal / Obesity Treatment News brief: bariatricpal.com
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News